Clin2
NCT07608796Possibly a fitNot yet recruiting

JAK inhibitor for depression in male football players

Depressive SymptomsCognitive Symptom

Treatments studied

Part of Brain & nervous system clinical trials.

This study tests a new medication (a JAK inhibitor) that may reduce brain inflammation and improve depression and thinking in male football players. It aims to see if this treatment helps with mood and cognitive function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
30 years to 55 years
Study type
Interventional

Who can take part

  • You must be male
  • You must have played tackle football for at least 11 years
  • You must be between 30 and 55 years old
  • You must have a current or partially remitted diagnosis of major depression or bipolar depression
  • You must have moderate to severe depressive symptoms (e.g., a score above 10 on a depression scale)
  • You must not have certain medical conditions (autoimmune disorders, infections, cancer, unstable organ disease, blood clots, stroke, recent major surgery, or cirrhosis)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07003997Recruiting· Phase 2
JAK inhibitor for depression with inflammation

This trial tests a JAK inhibitor (a type of anti-inflammatory drug) for depression that is linked to inflammation. If you have depression or bipolar depression and a high CRP level (a marker of inflammation), you may be eligible.

Atlanta, Georgia
NCT05849038Recruiting· Phase 2
Treating inflammation to improve depression in HIV

This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).

Atlanta, Georgia
NCT05452564Recruiting· Phase 2
Baricitinib to help reduce HIV in the brain

This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.

Atlanta, Georgia
NCT06793397Recruiting· Phase 3
Study of an experimental psychedelic-like drug for depression (CYB003)

This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.

Birmingham, Alabama
NCT06136546Recruiting· Phase 2
Infliximab for depression with cognitive problems

This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.

Boston, Massachusetts
NCT06687551Recruiting· Phase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis

This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.

Toulouse, Occitanie

Hear when a new Depressive Symptoms trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.